文献速递前列腺癌

诊断至手术时间对不良中危至极高危局限性前列腺癌的影响

Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer.
PubMed 文献 · BJU Int · 2019-01-27

该回顾性研究纳入2303例活检GG≥3且6个月内行根治性前列腺切除术的患者,比较活检至手术<3个月与3-6个月两组的肿瘤学结局。结果显示各GG组间辅助治疗率、病理结局及2/5年BCRFS、2/5/10年MFS均无显著差异。结论认为诊断后等待至6个月行RP不增加不良结局风险。

要点

  • 对于GG≥3局限性前列腺癌,诊断后3-6个月行RP与<3个月相比肿瘤学结局无显著差异。
  • 各GG组辅助治疗率、PSM、EPE、SVI、LNI在两组间均无显著差异。
  • 各GG组2/5年BCRFS及2/5/10年MFS在两组间均无显著差异。

核心结论

  • 对于不良中危至极高危临床局限性前列腺癌,诊断后等待至6个月行根治性前列腺切除术与不良结局无关。

研究设计与样本

  • 回顾性研究,纳入2005-2018年在本机构诊断GG≥3且6个月内行RP的2303例患者,按活检至RP时间分为<3个月和3-6个月两组。

主要发现

  • 2303例中GG3占54%(1244例)、GG4占26%(608例)、GG5占20%(451例),72%在<3个月行RP。
  • 各GG组辅助治疗率、PSM、EPE、SVI、LNI在<3个月与3-6个月组间无显著差异。
  • 1568例随访>1年,各GG组2年和5年BCRFS在两组间无显著差异(GG3 P=0.6;GG4 P=0.4;GG5 P=0.2)。
  • 各GG组2/5/10年MFS在两组间无显著差异(GG3 P=0.4;GG4 P=0.8;GG5 P=0.9),GG5因随访有限无法计算10年MFS。

临床怎么用

  • 对于不良中危至极高危局限性前列腺癌患者,诊断后6个月内安排RP是合理的,无需因等待3-6个月而过度担忧肿瘤学风险。

局限性

  • 本研究为单中心回顾性设计。
  • GG5患者随访时间有限,无法计算10年MFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of length of time from diagnostic biopsy to radical prostatectomy (RP) on oncological outcomes amongst men diagnosed with unfavourable intermediate- to very-high-risk clinically localised prostate cancer. PATIENTS AND METHODS: We performed a retrospective review of men with a diagnosis of grade group (GG) ≥3 prostate cancer on biopsy, who underwent RP within 6 months of diagnosis, at our institution between 2005 and 2018. We assessed patient demographics, pre-biopsy disease characteristics, and receipt of neoadjuvant therapy. We categorised time between biopsy and RP into two intervals: <3 and 3-6 months. For each GG, we compared receipt of adjuvant therapy, pathological outcomes at RP (positive surgical margin [PSM], extraprostatic extension [EPE], seminal vesicle invasion [SVI], and lymph node involvement [LNI]), risk of 2- and 5-year biochemical recurrence-free survival (BCRFS), and 2-, 5-, and 10-year metastasis-free survival (MFS) between patients who underwent RP at <3 vs 3-6 months after diagnosis. RESULTS: Amongst 2303 men who met the study inclusion criteria, 1244 (54%) had GG 3, 608 (26%) had GG 4, and 451 (20%) had GG 5 disease. In all, 72% underwent RP at <3 months after diagnosis. For each diagnostic GG, there was no significant difference in rates of adjuvant therapy, PSM, EPE, SVI, or LNI in men who had RP at <3 vs 3-6 months after diagnosis. In all, 1568 men had follow-up after RP of >1 year. For each diagnostic GG, there was no significant difference in 2- and 5-year BCRFS between patients who had RP at <3 vs 3-6 months after diagnosis (GG 3: 78% vs 83% and 69% vs 66%, respectively, P = 0.6; GG 4: 68% vs 74% and 51% vs 57%, respectively, P = 0.4; GG 5: 58% vs 74% and 48% vs 54%, respectively, P = 0.2). Similarly, for each diagnostic GG, there was no significant difference in 2-, 5-, and 10-year MFS between patients who had RP at <3 vs 3-6 months after diagnosis, although we were not able to calculate 10-year MFS for patients with GG 5 disease due to limited follow-up in that group (GG 3: 98%, 92%, and 84% vs 97%, 95%, and 91%, respectively, P = 0.4; GG 4: 97%, 90%, and 72% vs 94%, 91%, and 81%, respectively, P = 0.8; GG 5: 89% and 81% vs 91% and 71%, respectively, P = 0.9). CONCLUSIONS: Waiting for RP up to 6 months after diagnosis is not associated with adverse outcomes amongst patients with unfavourable intermediate- to very-high-risk prostate cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Gupta N, Bivalacqua TJ, Han M, et al. Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. BJU Int. 2019. PMID: 30570825. doi:10.1111/bju.14659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。